Characteristic | Baseline values (nā=ā32) |
---|---|
Sex | |
Male | 17 (53.1%) |
Female | 15 (46.9%) |
ECOG performance status | |
0 | 17 (53.1%) |
1 | 15 (46.9%) |
Mean age (range) - years | 65.4 (20ā85) |
M-stage | |
M1a | 4 (12.5%) |
M1b | 4 (12.5%) |
M1c | 24 (75.0%) |
Visceral metastases | 28 (87.5%) |
Non visceral metastases | 4 (12.5%) |
LDH level | |
</=Upper limit of the normal range | 18 (56.3%) |
> Upper limit of the normal range | 14 (43.8%) |
Number of previous therapies | |
1 | 17 (53.1%) |
2 | 7 (21.9%) |
3 | 4 (12.5%) |
ā„4 | 4 (12.5%) |
Previous anticancer treatment | |
Chemotherapy* | 29 (90.6%) |
Immunotherapy** | 12 (37.5%) |
Other anticancer therapy*** | 8 (25.0%) |
Data are number (%) or mean. *Carboplatin, Cisplatin, DTIC, Fotemustine, Gemcitabine, Melphalan, Paclitaxel, Treosulfan, Vindesine, **IFN, Ipilimumab, Thymosin, ***CNTO, Genasense, Imatinib, Sorafenib, STA-4783-08.